Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
暂无分享,去创建一个
P. Wilkinson | R. James | P. Canney | P A Canney | M Moore | P M Wilkinson | R D James | M. Moore
[1] R. J. Johnson,et al. Abdomino-pelvic computed tomography in the management of ovarian carcinoma. , 1983, Radiology.
[2] J. van Nagell,et al. Multiple biochemical markers in patients with gynecologic malignancies , 1980, Cancer.
[3] E. Newlands,et al. Chemotherapy of advanced malignant teratomas. , 1980, British Journal of Cancer.
[4] J. Barlow,et al. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. , 1982, Cancer research.
[5] R. Bast,et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. , 1983, American journal of clinical pathology.
[6] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.
[7] C. Cohen,et al. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). , 1983, American journal of obstetrics and gynecology.
[8] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.